Rebamipide protects against experimentally induced intestinal ischemia/reperfusion-promoted liver damage: Impact on SIRT1/β-catenin/FOXO1and NFκB signaling

Nisreen E. Elwany,Amal El. Salem,Noura Mostafa Mohamed,Sama S. Khalil,Nevertyty M. Mahmoud

INTERNATIONAL IMMUNOPHARMACOLOGY（2023）

引用 1|浏览1

暂无评分

摘要

•Intestinal I/R is a life-threatening condition associated with high morbidity and mortality rates.•Intestinal I/R is suggested to be the principal cause of multi-organ failure including the liver.•Rebamipide (Reba) is a well-known gastroprotective drug.•Reba is suggested to mitigate intestinal I/R-associated liver injury through modulation of SIRT1/β-catenin/ FOXO1-NFκB signaling mechanisms.

查看译文

关键词

Intestinal I/R,Liver injury,Rebamipide,SIRT1/β-catenin signaling pathway

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要